Economic assesment of the routine use of Oncotype DX® assay for early breast cancer in Franche-Comte region.

Nerich V1, Curtit E2, Bazan F3, Montcuquet P3, Villanueva C3, Chaigneau L3, Cals L3, Méneveau N3, Dobi E3, Altmotlak H3, Algros MP3, Choulot MJ4, Nallet G5,Limat S1, Mansion S4, Pivot X2.

Author information

Abstract

Oncotype DX® has been validated as quantifying the likelihood of distant recurrence at 10 years and overall chemotherapy benefit in patients with estrogen-receptor-positive and HER-2-negative early breast cancer. In 2012, this genomic signature was routinely available for patients in Franche-Comté, France. Patients eligible for Oncotype DX® testing had a ER-positive, HER-2-négative early breast cancer with a nodal involvement limited to 0 or 1 positive-node without extracapsular spread; an adjuvant chemotherapy was indicated based on usual prognostic factors. The aim was to assess the economic impact of Oncotype DX® testing in a French region. A cost-minimisation analysis from the French Public Healthcare System perspective was performed. The availability of Oncotype DX® in Franche-Comté, France, and its use in clinical routine allowed a decrease of 73 % of adjuvant chemotherapy without increase of the cost of the patients' management and with a potential reduction of the cost for the French Public Healthcare System. This strategy was successful and may allow the reimbursement of this test in France for patients with early breast cancer.